When Eczema Medicine Seems Not to Work: What Electronic Monitoring Can—and Cannot—Show
When eczema remains active, it is tempting to conclude that a prescribed medicine has failed. Before changing treatment, the team needs to understand how the plan worked in real life: whether the medicine was obtained, which areas were treated, what was uncomfortable and where instructions became difficult. This is an investigation of barriers, not a test of character.
What electronic monitoring measured
A 2007 study gave 37 children topical triamcinolone ointment with twice-daily instructions and monitored container use over eight weeks. Twenty-six completed follow-up. Average recorded adherence was 32%, with greater use near office visits and a rapid decline afterward. Families were informed about the monitoring at the end.
The substantial loss to follow-up limits interpretation. Electronic opening records also do not prove the correct amount reached the correct skin area. The result is not a finding that all families use one-third of treatment correctly, and the study regimen is not a prescription for another child.
What visit timing might change
A 2013 analysis of five monitored clinical trials found average adherence ranging from 32% to 93%. Longer time to the first return visit was associated with lower adherence. The comparison suggests that early follow-up may be a useful support, but differences among studies prevent treating it as proof that one appointment schedule will work for everyone.
An opening-count pattern can prompt a useful question without revealing why it occurred. A child may dislike a texture, the family may not have enough medicine or a caregiver may be uncertain which tube goes where. Those barriers need different solutions.
| Barrier to explore | A specific question |
|---|---|
| Access | Was the medicine filled and available throughout the course? |
| Instructions | Can the family describe area, amount and frequency? |
| Tolerance | Did pain, burning or texture prevent use? |
| Handoffs | Do caregivers share one clear plan? |
| Follow-up | Who can answer a problem before the next routine visit? |
Describe the actual routine honestly
Bring the containers and explain what happened during an ordinary week. If a dose was missed or the plan was changed, that information helps the clinician distinguish a medication's effect from incomplete or incorrect exposure. It should not be used to shame a family or dismiss persistent symptoms without examination.
Do not respond to a poor week by applying extra medicine to “catch up.” Ask for the individual instructions. If the written plan is too complicated, discuss which steps are necessary and how they can be made clearer without losing treatment safety.
Review treatment concerns separately
Our TOPICOP education article shows that improving knowledge does not automatically change fear or use. More instructions alone may not resolve the barrier. The NIAMS care overview emphasizes treatment tailored to the person's disease and response, with regular follow-up.
Our telehealth preparation guide can help organize that contact when appropriate. Ask whether an earlier check, demonstration or written body-area plan would help. If treatment has truly been used as directed and eczema remains active, say that clearly too. Reviewing practical use should support an appropriate next decision, not indefinitely delay effective care.
Use the review to choose the right next step
A persistent eruption despite the reported plan may call for a diagnostic review as well as a discussion of use. Patch testing during dupilumab treatment illustrates one specialist investigation of a possible additional cause. For severe refractory hand eczema, the BACH trial of alitretinoin involved a specific systemic option and important safety requirements. Neither discussion means that all apparent treatment failure is explained by missed applications.
Sources and reading notes
- 2007 electronic-monitoring study
- 2013 comparison of five monitored trials
- NIAMS: individualized care and follow-up
Prepared by the Dr. Arsy Editorial Team. Sources checked November 8, 2026. Educational information; this article does not imply independent clinician review. PubMed indexing is not NIH endorsement. The cited researchers do not endorse #003. The product image is an AI-created editorial scene based on the actual jar, not a patient photograph or a study result.